Skip to main content
. 2022 Jul 18;19(14):8723. doi: 10.3390/ijerph19148723

Figure 2.

Figure 2

PAD-4 level (pg/mL) before (week 0) and during (week 4, week 12) therapy with: MTX (therapy 1, n = 20), anti-TNFα (therapy 2, n = 20) and anti-IL-17A (therapy 3, n = 10) in patients with plaque psoriasis compared with a control consisting of healthy volunteers (n = 16). * indicates a statistically significant difference (p < 0.05) between weeks: 0 and 12.